OOS Investigation Procedural Map

⚗️

OOS Result Obtained — Investigation Triggered Immediately

Any analytical result that falls outside established acceptance criteria in the specification, pharmacopeial standard, drug application or regulatory filing triggers a mandatory investigation under 21 CFR 211.192. This includes in-process tests, raw material testing and finished product release testing. No retesting may occur before investigation initiation.

21 CFR 211.192 · 21 CFR 211.165(f) · FDA OOS Guidance 2022 Section III

Phase I — Laboratory Investigation Complete within 3–10 business days

1Notify supervisor and QA unit immediately

Analyst reports OOS result to laboratory supervisor before any further action. QA unit is notified. Original result is preserved in raw data with no alterations. Documentation timestamped at point of discovery.

21 CFR 211.192 · 21 CFR 211.194

↓

2Preserve original sample and reference standards

Do not discard the original test sample, reference standards, reagents or solutions. All materials used in the original analysis must be retained for investigation review. Instrument raw data files preserved with audit trail intact.

21 CFR 211.194 · ALCOA+ data integrity

↓

3Review original analytical procedure and execution

Laboratory supervisor reviews: calculation errors, instrument calibration status, standard preparation, reagent expiry, column condition, sample preparation technique, environmental conditions during analysis and analyst training records for this method.

21 CFR 211.160(b) · FDA OOS Guidance Section IV.A

↓

Is an assignable laboratory cause identified with objective evidence?

"Analyst error" alone is NOT sufficient. Cause must be specific, documented and reproducible.

YES → Step 4 NO → Step 5

↓ YES

4Document laboratory error with objective evidence

Assignable cause must be documented with specific objective evidence — not vague attribution. Examples: wrong diluent volume confirmed by balance printout, expired reference standard confirmed by certificate date. Supervisor and QA must approve invalidation before any retest.

FDA OOS Guidance Section IV.A.2 · Barr Laboratories precedent

↓

QA unit approves laboratory error invalidation?

YES → Retest NO → Step 5

↓ YES — QA approved invalidation

4aConduct single retest — fresh sample preparation

One retest by a second qualified analyst. Fresh sample preparation. Same validated method. Result used for batch disposition. If retest also OOS, proceed to Phase II regardless of laboratory error conclusion. Retesting to obtain a passing result is prohibited.

FDA OOS Guidance Section V · 21 CFR 211.192

↓

Retest result within specification?

YES → Document and proceed to disposition NO → Phase II

↓ NO assignable cause found

5No laboratory cause found — escalate to Phase II

Phase I complete. No assignable laboratory error identified with objective evidence. Manufacturing investigation required. QA unit formally opens Phase II. Batch remains on hold.

FDA OOS Guidance Section IV.B · 21 CFR 211.192

Phase II — Full Manufacturing Investigation Total investigation max 45 days

6QA formally opens Phase II investigation

Quality unit opens formal investigation record. Assigns investigation lead. Batch placed on quarantine hold. Manufacturing batch record retrieved and reviewed. All relevant personnel identified for interview. Investigation timeline documented.

21 CFR 211.192 · ICH Q10 Section 3.2

↓

7Review batch production records in full

Complete batch record review: raw material COAs and test results, equipment calibration and cleaning records, in-process test results, deviation records, environmental monitoring data for manufacturing period, personnel training records and any batch-specific observations or events.

21 CFR 211.188 · 21 CFR 211.192

↓

8Conduct root cause investigation with documented methodology

Apply documented RCA methodology: 5 Why for single-factor events, Ishikawa fishbone for multi-factor events, FMEA for risk assessment. Human error is NOT an acceptable root cause — investigate why the system allowed the error. Full analytical pathway must be documented.

ICH Q9(R1) 2023 · FDA OOS Guidance Section IV.B

↓

Is a manufacturing root cause identified?

YES → Step 9 NO → Step 10

↓

9Additional testing if scientifically justified

If additional testing is needed to characterise the failure, the number of additional tests must be pre-defined before testing begins. Cannot retest until passing result obtained. All results — passing and failing — must be reported and included in the investigation. Average of passing results only is prohibited.

FDA OOS Guidance Section V.B · Barr Laboratories decision

↓

Do additional test results confirm OOS?

YES → Reject batch NO → Document and assess

↓

10Implement CAPA with pre-defined effectiveness criteria

CAPA must address identified root cause — not symptom. Effectiveness criterion defined before implementation. Scheduled effectiveness check with measurable threshold. Scope extension to other batches documented. CAPA closure requires QA approval and verified effectiveness.

21 CFR 211.192 · ICH Q10 Section 3.2.2 · FDA CAPA guidance

↓

11QA review and batch disposition decision

Quality unit reviews complete investigation package: Phase I findings, Phase II root cause, all test results, CAPA plan, scope extension conclusion. QA approves or rejects the investigation before batch disposition. No batch may be released or rejected before investigation completion.

21 CFR 211.165(f) · 21 CFR 211.192

↓

Does investigation support batch release?

YES → Release NO → Reject

↙ YES ↘ NO

✓ BATCH RELEASED
Full documentation retained
CAPA monitoring active

✕ BATCH REJECTED
Quarantine confirmed
CAPA required

⚠ Mandatory Scope Extension — 21 CFR 211.192

Other batches — same product Every other batch of the same drug product manufactured in the same period or using the same materials must be assessed. Conclusion must be documented even if no impact is identified.

Other products — same failure mode Other drug products associated with the same specific failure or discrepancy must be assessed. Equipment, raw material supplier and process step commonality are the primary assessment criteria.

Distributed batches 21 CFR 211.192 requires investigation whether or not the batch has already been distributed. A released batch associated with the OOS failure must be assessed for recall or field alert requirements.

Never do this

Retest until a passing result is obtained. Average passing results while discarding OOS results. Attribute root cause to "analyst error" without objective documented evidence. Begin retesting before investigation is initiated.

Documentation required

All raw data preserved with audit trail. Every decision point documented with rationale. All test results reported — passing and failing. Timestamps contemporaneous. QA approval at each phase transition.

Timelines

Phase I: 3–10 business days. Total investigation: 45 days maximum. Extensions require documented QA justification. Open OOS investigations beyond 30 days are a standard FDA 483 finding.

Key regulations

21 CFR 211.192 — primary investigation requirement. 21 CFR 211.165(f) — batch disposition. 21 CFR 211.194 — laboratory records. FDA OOS Guidance 2022. Barr Laboratories court decision.